These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35577812)

  • 21. Modularly Designed Peptide Nanoprodrug Augments Antitumor Immunity of PD-L1 Checkpoint Blockade by Targeting Indoleamine 2,3-Dioxygenase.
    Han X; Cheng K; Xu Y; Wang Y; Min H; Zhang Y; Zhao X; Zhao R; Anderson GJ; Ren L; Nie G; Li Y
    J Am Chem Soc; 2020 Feb; 142(5):2490-2496. PubMed ID: 31944687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy.
    Lu K; He C; Guo N; Chan C; Ni K; Weichselbaum RR; Lin W
    J Am Chem Soc; 2016 Sep; 138(38):12502-10. PubMed ID: 27575718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
    Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
    ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrasound-Driven Biomimetic Nanosystem Suppresses Tumor Growth and Metastasis through Sonodynamic Therapy, CO Therapy, and Indoleamine 2,3-Dioxygenase Inhibition.
    Zhang D; Lin Z; Zheng Y; Song J; Li J; Zeng Y; Liu X
    ACS Nano; 2020 Jul; 14(7):8985-8999. PubMed ID: 32662971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
    Yentz S; Smith D
    BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells.
    Fan Q; Zuo J; Tian H; Huang C; Nice EC; Shi Z; Kong Q
    J Exp Clin Cancer Res; 2022 May; 41(1):162. PubMed ID: 35501823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy.
    Hu Z; Zheng B; Xu J; Gao S; Lu W
    Nanotechnology; 2020 May; 31(29):295101. PubMed ID: 32203949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multifunctional Cascade Bioreactor Based on Hollow-Structured Cu
    Chang M; Wang M; Wang M; Shu M; Ding B; Li C; Pang M; Cui S; Hou Z; Lin J
    Adv Mater; 2019 Dec; 31(51):e1905271. PubMed ID: 31680346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cascade nanozymes based on the "butterfly effect" for enhanced starvation therapy through the regulation of autophagy.
    Yao H; Gong X; Geng M; Duan S; Qiao P; Sun F; Zhu Z; Du B
    Biomater Sci; 2022 Jul; 10(14):4008-4022. PubMed ID: 35726640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Glucose/Oxygen-Exhausting Nanoreactor for Starvation- and Hypoxia-Activated Sustainable and Cascade Chemo-Chemodynamic Therapy.
    Guo Y; Jia HR; Zhang X; Zhang X; Sun Q; Wang SZ; Zhao J; Wu FG
    Small; 2020 Aug; 16(31):e2000897. PubMed ID: 32537936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
    Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
    Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring ROS Responsive Fe
    Zhang L; Qiu M; Wang R; Li S; Liu X; Xu Q; Xiao L; Jiang ZX; Zhou X; Chen S
    Angew Chem Int Ed Engl; 2024 May; 63(22):e202403771. PubMed ID: 38551448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-driven nanoprodrug platform with enhanced ferroptosis for synergistic photothermal-IDO immunotherapy.
    Huang P; Yang Y; Wang W; Li Z; Gao N; Chen H; Zeng X
    Biomaterials; 2023 Aug; 299():122157. PubMed ID: 37196407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
    Selvan SR; Dowling JP; Kelly WK; Lin J
    Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein-Delivering Nanocomplexes with Fenton Reaction-Triggered Cargo Release to Boost Cancer Immunotherapy.
    Li X; Zhou Q; Japir AAMM; Dutta D; Lu N; Ge Z
    ACS Nano; 2022 Sep; 16(9):14982-14999. PubMed ID: 36017992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disruption of dual homeostasis by a metal-organic framework nanoreactor for ferroptosis-based immunotherapy of tumor.
    Zhang K; Ma Z; Li S; Wu Y; Zhang J; Zhang W; Zhao Y; Han H
    Biomaterials; 2022 May; 284():121502. PubMed ID: 35390708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy.
    Dai L; Li X; Yao M; Niu P; Yuan X; Li K; Chen M; Fu Z; Duan X; Liu H; Cai K; Yang H
    Biomaterials; 2020 May; 241():119901. PubMed ID: 32109706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
    Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ
    Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.